Returning for the 4th time, ICI Boston is the definitive forum focused exclusively on how to deliver maximum clinical benefit through immune checkpoint modulation.
Rather than attempting to cover the entire IO space and only providing superficial insights, this conference has the focus required to drill down into the real details. Discover how to overcome key preclinical, translational and clinical drug development challenges encountered in the development of checkpoint modulators.
ICI Boston will unite industry leaders including Merck, BMS, Genentech and Novartis to share in-depth case studies on topics such as overcoming resistance to checkpoint blockade, identifying translational biomarkers and understanding the mechanistic rationale behind combination strategies.
Join leading drug developers who have successfully developed IO therapeutics and ensure you make the right decisions with your IO pipeline.
Please note: earlybird discounts are available. Secure your place early for maximum savings. Visit the event website for full details on discounts.
Standard Rate - Conference 2 Workshops: USD 3997,
Standard Rate - Conference 1 Workshop: USD 3398,
Standard Rate - Conference Only: USD 2799,
Standard Rate - Workshop Only: USD 699.
Speakers: Roger Dansey (Merck), Israel Lowy (Regeneron), Corinne Reimer (AstraZeneca), Bernard Fox (Providence Cancer Center), Bill Grossman (Genentech), Amy Peterson (BeiGene), Lata Jayaraman (Seres Therapeutics), Jochem Gokemeijer (Bristol-Myers Squibb), Catherine Sabatos-Peyton (Novartis).
Time: 9:00 am to 4:00 pm.